The future of drug discovery is at Envisagenics

We use Artificial Intelligence and Machine Learning to unlock the therapeutic potential of RNA.

Our platform leverages RNA sequencing data and AI/ML algorithms to identify, test and validate drug targets with greater speed and precision than traditional methods.

Know more

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

Traditional methods to detect RNA splicing variation have been limited – Envisagenics’ SpliceCore^® platform is able to scale the discovery of splicing-derived drug targets.

SpliceCore^® not only identifies new targets for RNA therapeutics but also explains the mechanism by which the antisense drugs regulate the splicing event, leading to more transparent and verifiable AI/ML predictions.

SpliceIO^TM, the immunotherapeutic branch of SpliceCore^®, identifies tumor specific neoepitopes targetable with a variety of antibody-based modalities.

SpliceCore^® Benchmarks

250x

larger search space for target discovery with SpliceCore’s exon-centric approach

78%

experimental validation rate for SpliceCore-discovered targets

100%

drug target candidates derived from disease-specific splicing events

View our pipeline

News

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

August 3, 2022

Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022

March 2, 2022

Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform

September 29, 2021

The future of drug discovery is at Envisagenics

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

SpliceCore^® Benchmarks

News

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022

Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform

Investors

Partners

Member

Foundations

The future of drug discovery is at Envisagenics

Envisagenics’ SpliceCore® software platform discovers novel targets to develop successful therapies

SpliceCore® Benchmarks

News

Investors

Partners

Member

Foundations

Envisagenics’ SpliceCore^® software platform discovers novel targets to develop successful therapies

SpliceCore^® Benchmarks